TBEL Project 1

TBEL项目1

基本信息

项目摘要

PROJECT 1 - ABSTRACT There are two distinct pathways to invasive neoplasia in the pancreas – the more common non-cystic (pancreatic intraepithelial neoplasia or PanIN) and cystic (mostly, intraductal papillary mucinous neoplasm or IPMN). Both PanIN and IPMNs occur at significantly higher rates in the population than invasive cancer, reiterating that only a fraction of precursor lesions progress to pancreatic ductal adenocarcinoma (PDAC), but determining which patient will progress is currently not possible. PanINs and IPMNs are both characterized by the common occurrence of oncogenic KRAS mutations, while the latter also harbors concomitant “hotspot” GNAS mutations in 2/3rd of cases. How these early epithelial alterations and their crosstalk with the tumor microenvironment (TME) impacts progression to cancer remains understudied. The formation of early pancreatic precursors is accompanied by the expansion of a heterogeneous fibroblast population. In advanced disease, fibroblasts become cancer associated fibroblasts (CAFs). Little is known about precursor lesion associated fibroblasts (PAFs), including prevalent differences between the two precursor subtypes. Our preliminary data show that fibroblast reprogramming occurs in early pancreatic lesions, and leads to expression of IL6, and IL33. While IL6 is secreted and known to regulate the immune microenvironment, IL33 is prevalently nuclear in fibroblasts. Interestingly, IPMNs also have extremely elevated epithelial nuclear IL33. IL33 contains a DNA binding domain and is known to regulate transcription. Based on these observations, we propose to study the mechanisms of fibroblast reprogramming and comparing fibroblast gene expression in PanINs and IPMNs (Aim 1). Further, we will study the role of fibroblast IL33 in lesion progression and establishment of the precursor lesion microenvironment (PME) in PanIN and IPMN (Aim 2). Lastly, we will determine how epithelial IL33 in IPMNs regulates the PME as well as progression to malignancy (Aim 3). We will integrate the mouse model and in vitro studies with primary human tissue and organoids generated in the Wood laboratory (see Project 3). Together, these studies will shed light on the composition and role of PAFs in different premalignant lesions of the pancreas.
项目1--摘要 胰腺侵袭性肿瘤有两种不同的途径--更常见的是非囊性病变。 (胰腺上皮内瘤变或Panin)和囊性(主要是导管内乳头状粘液 肿瘤或IPMN)。PANIN和IPMN在人群中的发生率明显高于侵袭性 癌症,重申只有一小部分前驱病变进展为胰腺导管腺癌 (PDAC),但目前无法确定哪个患者会进步。PAINS和IPMN都是 以常见的致癌KRAS突变为特征,而后者也 伴随的“热点”GNAS突变在2/3的病例中。这些早期的上皮改变和它们的串扰 肿瘤微环境(TME)对肿瘤进展的影响尚不清楚。形成了一种 早期胰腺前体细胞伴随着异质成纤维细胞群体的扩张。在……里面 晚期疾病时,成纤维细胞成为癌症相关成纤维细胞(CAF)。人们对前兆知之甚少 病变相关成纤维细胞(PAF),包括两种前体亚型之间的普遍差异。我们的 初步数据显示,成纤维细胞重编程发生在早期胰腺病变中,并导致表达 白介素6和白介素33。虽然IL6是分泌的,并且已知可以调节免疫微环境,但IL33普遍存在 成纤维细胞中的核。有趣的是,IPMN也有极高的上皮核IL33。IL33包含一个 DNA结合域,并被认为是调节转录。基于这些观察,我们建议研究 PAINS和IPMNS中成纤维细胞重编程机制及成纤维细胞基因表达的比较 (目标1)。进一步,我们将研究成纤维细胞IL33在病变进展中的作用和前体的建立 Panin和IPMN的病变微环境(PME)(目标2)。最后,我们将确定上皮性IL33是如何在 IPMns调节PME以及向恶性肿瘤的进展(目标3)。我们将把鼠标模型和 对伍德实验室产生的原生人体组织和有机类化合物进行体外研究(见项目3)。 总之,这些研究将阐明PAF在不同癌前病变中的组成和作用。 胰腺。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marina Pasca Di Magliano其他文献

Marina Pasca Di Magliano的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marina Pasca Di Magliano', 18)}}的其他基金

Establishment and regulation of the immune suppressive microenvironment in pancreatic cancer
胰腺癌免疫抑制微环境的建立与调控
  • 批准号:
    10460794
  • 财政年份:
    2022
  • 资助金额:
    $ 37万
  • 项目类别:
TBEL Project 1
TBEL项目1
  • 批准号:
    10708201
  • 财政年份:
    2022
  • 资助金额:
    $ 37万
  • 项目类别:
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment
靶向成纤维细胞-免疫细胞串扰以缓解胰腺癌微环境中的免疫抑制
  • 批准号:
    10535373
  • 财政年份:
    2022
  • 资助金额:
    $ 37万
  • 项目类别:
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment
靶向成纤维细胞-免疫细胞串扰以缓解胰腺癌微环境中的免疫抑制
  • 批准号:
    10688108
  • 财政年份:
    2022
  • 资助金额:
    $ 37万
  • 项目类别:
Gli Activity in the Pancreas: Inflammation, Tissue Repair and Cancer
胰腺中的 Gli 活性:炎症、组织修复和癌症
  • 批准号:
    8658023
  • 财政年份:
    2010
  • 资助金额:
    $ 37万
  • 项目类别:
Gli Activity in the Pancreas: Inflammation, Tissue Repair and Cancer
胰腺中的 Gli 活性:炎症、组织修复和癌症
  • 批准号:
    8259535
  • 财政年份:
    2010
  • 资助金额:
    $ 37万
  • 项目类别:
Gli Activity in the Pancreas: Inflammation, Tissue Repair and Cancer
胰腺中的 Gli 活性:炎症、组织修复和癌症
  • 批准号:
    8103208
  • 财政年份:
    2010
  • 资助金额:
    $ 37万
  • 项目类别:
Gli Activity in the Pancreas: Inflammation, Tissue Repair and Cancer
胰腺中的 Gli 活性:炎症、组织修复和癌症
  • 批准号:
    8462231
  • 财政年份:
    2010
  • 资助金额:
    $ 37万
  • 项目类别:
Training Program in Organogenesis
器官发生培训计划
  • 批准号:
    10152628
  • 财政年份:
    1997
  • 资助金额:
    $ 37万
  • 项目类别:
Signaling and Tumor Microenvironment (STME)
信号传导和肿瘤微环境 (STME)
  • 批准号:
    10627253
  • 财政年份:
    1997
  • 资助金额:
    $ 37万
  • 项目类别:

相似国自然基金

炎性反应中巨噬细胞激活诱导死亡(activation-induced cell death,AICD)的机理研究
  • 批准号:
    30330260
  • 批准年份:
    2003
  • 资助金额:
    105.0 万元
  • 项目类别:
    重点项目

相似海外基金

放射線とNivo併用におけるImmunogenic cell deathの検証
辐射和 Nivo 组合的免疫原性细胞死亡验证
  • 批准号:
    23K24410
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Single cell level elucidation of local cell death-triggered regeneration mechanism in Arabidopsis
单细胞水平阐明拟南芥局部细胞死亡触发的再生机制
  • 批准号:
    24K17869
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Analysis of the association between the cell death and inflammation in monogenic autoinflammatory diseases
单基因自身炎症性疾病中细胞死亡与炎症的关联分析
  • 批准号:
    23K15335
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanism of Lipoxyptosis, lipid oxidation-dependent cell death
脂肪下垂、脂质氧化依赖性细胞死亡的分子机制
  • 批准号:
    23K14351
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The study on the relationship between regulated cell death and prion diseases
调节性细胞死亡与朊病毒病关系的研究
  • 批准号:
    22KJ0128
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Regulation of Cell Death in HIV Reservoirs
HIV 储存库细胞死亡的调控
  • 批准号:
    10674315
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
LITAF regulation of cell death and inflammatory responses
LITAF 调节细胞死亡和炎症反应
  • 批准号:
    10886166
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
Control of the programmed cell death machinery by the ubiquitin-proteasome system in neurons
神经元中泛素蛋白酶体系统对程序性细胞死亡机制的控制
  • 批准号:
    2884939
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
    Studentship
Characterisation of autolytic programmed cell death in Pseudomonas aeruginosa biofilms
铜绿假单胞菌生物膜中自溶程序性细胞死亡的表征
  • 批准号:
    BB/X008436/1
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
    Research Grant
Induction of cancer-selective cell death by intracellular self-assembly of molecules
通过细胞内分子自组装诱导癌症选择性细胞死亡
  • 批准号:
    23H01774
  • 财政年份:
    2023
  • 资助金额:
    $ 37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了